Yuwadee Boonyasit1, Wanida Laiwattanapaisal. 1. Graduate Program in Clinical Biochemistry & Molecular Medicine, Faculty of Allied Health Sciences, Chulalongkorn University, Bangkok 10330, Thailand.
Abstract
BACKGROUND: A method for acquiring albumin-corrected fructosamine values from whole blood using a microfluidic paper-based analytical system that offers substantial improvement over previous methods is proposed. RESULTS: The time required to quantify both serum albumin and fructosamine is shortened to 10 min with detection limits of 0.50 g dl(-1) and 0.58 mM, respectively (S/N = 3). The proposed system also exhibited good within-run and run-to-run reproducibility. The results of the interference study revealed that the acceptable recoveries ranged from 95.1 to 106.2%. The system was compared with currently used large-scale methods (n = 15), and the results demonstrated good agreement among the techniques. CONCLUSION: The microfluidic paper-based system has the potential to continuously monitor glycemic levels in low resource settings.
BACKGROUND: A method for acquiring albumin-corrected fructosamine values from whole blood using a microfluidic paper-based analytical system that offers substantial improvement over previous methods is proposed. RESULTS: The time required to quantify both serum albumin and fructosamine is shortened to 10 min with detection limits of 0.50 g dl(-1) and 0.58 mM, respectively (S/N = 3). The proposed system also exhibited good within-run and run-to-run reproducibility. The results of the interference study revealed that the acceptable recoveries ranged from 95.1 to 106.2%. The system was compared with currently used large-scale methods (n = 15), and the results demonstrated good agreement among the techniques. CONCLUSION: The microfluidic paper-based system has the potential to continuously monitor glycemic levels in low resource settings.
Authors: Margarita Ortiz-Martínez; Mirna González-González; Alexandro J Martagón; Victoria Hlavinka; Richard C Willson; Marco Rito-Palomares Journal: Curr Diab Rep Date: 2022-03-10 Impact factor: 5.430